These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 13344137)

  • 41. Serum ferritin concentration predicts hepatic fibrosis better than hepatic iron concentration in human HFE-Haemochromatosis.
    Wood MJ; Crawford DHG; Wockner LF; Powell LW; Ramm GA
    Liver Int; 2017 Sep; 37(9):1382-1388. PubMed ID: 28231420
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship of body iron stores to levels of serum ferritin, serum iron, unsaturated iron binding capacity and transferrin saturation in patients with iron storage disease.
    Beutler E; Felitti V; Ho NJ; Gelbart T
    Acta Haematol; 2002; 107(3):145-9. PubMed ID: 11978935
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparative study of the behavior of radioactive iron in idiopathic hemochromatosis and alcoholic cirrhosis].
    ROSSELIN G; KONDAKIS X; LUBETZKI J; GHATA J; TUBIANA M; AZERAD E
    Pathol Biol; 1960 Oct; 8():1833-44. PubMed ID: 13743663
    [No Abstract]   [Full Text] [Related]  

  • 44. [Iron-binding capacity of blood serum. III. Iron-binding capacity in hemorrhagic anemia and chronic infections].
    RECHENBERGER J
    Dtsch Z Verdau Stoffwechselkr; 1956; 16(4):162-9. PubMed ID: 13344138
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease.
    Giambattistelli F; Bucossi S; Salustri C; Panetta V; Mariani S; Siotto M; Ventriglia M; Vernieri F; Dell'acqua ML; Cassetta E; Rossini PM; Squitti R
    Neurobiol Aging; 2012 Aug; 33(8):1633-41. PubMed ID: 21514009
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Unusual increase in serum iron in a patient with hemochromatosis and acute hepatitis].
    Buhac I
    Med Pregl; 1971; 24(7):281-2. PubMed ID: 5134390
    [No Abstract]   [Full Text] [Related]  

  • 47. [Hemochromatosis, with consideration of blood iron and copper levels and of treatment with repeated venesection].
    CHRISTENSEN R
    Ugeskr Laeger; 1955 Apr; 117(15):445-51. PubMed ID: 14374104
    [No Abstract]   [Full Text] [Related]  

  • 48. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis?
    Adams PC
    Am J Gastroenterol; 2001 Feb; 96(2):567-9. PubMed ID: 11232708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical experience with early hemochromatosis].
    Bell H; Raknerud N; Try K; Rostad B; Leivestad T
    Tidsskr Nor Laegeforen; 1994 Jun; 114(15):1704-8. PubMed ID: 8079282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis.
    Barton JC; Barton JC; Acton RT; So J; Chan S; Adams PC
    Clin Gastroenterol Hepatol; 2012 Apr; 10(4):412-6. PubMed ID: 22265917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Secondary hypothyroidism in hereditary hemochromatosis: recovery after iron depletion.
    Hudec M; Grigerova M; Walsh CH
    Thyroid; 2008 Feb; 18(2):255-7. PubMed ID: 18205549
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Familial hemochromatosis: characteristics of the precirrhotic stage in a large kindred.
    Rowe JW; Wands JR; Mezey E; Waterbury LA; Wright JR; Tobin J; Andres R
    Medicine (Baltimore); 1977 May; 56(3):197-211. PubMed ID: 870791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload.
    Baldus WP; Fairbanks VF; Dickson ER; Baggenstoss AH
    Mayo Clin Proc; 1978 Mar; 53(3):157-65. PubMed ID: 628226
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypogonadism and sexual dysfunction in hemochromatosis: the effects of cirrhosis and diabetes.
    Cundy T; Bomford A; Butler J; Wheeler M; Williams R
    J Clin Endocrinol Metab; 1989 Jul; 69(1):110-6. PubMed ID: 2732293
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Iron metabolism during treatment of idiopathic haemochromatosis.
    MACGREGOR AG; RAMSAY WN
    Lancet; 1957 Dec; 273(7009):1314-6. PubMed ID: 13492635
    [No Abstract]   [Full Text] [Related]  

  • 56. Hemochromatosis and pregnancy: iron stores in the Hfe-/- mouse are not reduced by multiple pregnancies.
    Neves JV; Olsson IA; Porto G; Rodrigues PN
    Am J Physiol Gastrointest Liver Physiol; 2010 Apr; 298(4):G525-9. PubMed ID: 20110460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hemochromatosis: platelets and aspartate aminotransferase are useful high-degree fibrosis marker.
    Castiella A; Zapata E; Otazua P
    Hepatology; 2009 May; 49(5):1781; author reply 1781-2. PubMed ID: 19402116
    [No Abstract]   [Full Text] [Related]  

  • 58. [Iron binding capacity of the blood serum at various ages].
    RECHENBERGER J
    Z Alternsforsch; 1955 Oct; 9(1-2):98-105. PubMed ID: 13300197
    [No Abstract]   [Full Text] [Related]  

  • 59. [Clinical evaluation of the content of serum iron in liver cirrhosis in children].
    Plaksina GV; Dedikova LA
    Pediatriia; 1975 Mar; (3):61-2. PubMed ID: 1118242
    [No Abstract]   [Full Text] [Related]  

  • 60. Monocyte membrane ferritin in hemochromatosis.
    Adams PC; Flanagan PR; Chau L; White M; Lazarovits A
    Clin Invest Med; 1991 Oct; 14(5):402-8. PubMed ID: 1742918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.